Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

AstraZeneca Rebuilds Its R&D, With Payers In Mind

Executive Summary

When Martin Mackay joined AstraZeneca PLC as president, global research & development, from Pfizer Inc. one year ago, one of his objectives was to "put AstraZeneca's R&D back on the map."
Advertisement

Related Content

AstraZeneca’s R&D Restructuring Follows Hot Spot Trend
Biopharma In 2011: A Year Of Transition
China’s Hua Medicine Licenses Worldwide Rights To Roche Diabetes Compound, More Deals On The Way
AstraZeneca Takes Impairment Charge After Olaparib, TC-5214 Setbacks
Medimmune Bets on Pain: Why The Large Molecule Specialist Thinks It Can Win
AstraZeneca Rebuilds R&D Amid Growing Near-Term Pressures
AstraZeneca, HealthCore Launch Outcomes Data Project, Seek Multi-Stakeholder Consortium
Brilinta "Complete Response" Letter Suggests FDA Unswayed On U.S. Efficacy
Brilinta "Complete Response" Letter Suggests FDA Unswayed On U.S. Efficacy
Pfizer's Global R&D Network: Rapid Integration Means Doing More With Less

Topics

Advertisement
UsernamePublicRestriction

Register

PS053546

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel